Anne Marijn Kramer

Anne Marijn Kramer

Auto-generated profile, based on publicly available information

Anne Marijn Kramer

Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2015 in OncoImmunology
Verified
Journal Article
Open access
AKAstrid Olsnes Kittang
Astrid Olsnes Kittang
SKShahram Kordasti
Shahram Kordasti
KSKristoffer Evebø Sand
Kristoffer Evebø Sand
BCBenedetta Costantini
Benedetta Costantini
AKAnne Marijn Kramer
Anne Marijn Kramer
GMGhulam J. Mufti
Ghulam J. Mufti
Although the role of CD4+ T cells and in particular Tregs and Th17 cells is established in myelodysplastic syndrome(MDS), the contribution of other components of immune system is yet to be elucidated fully. In this study we investigated the number and function of myeloid derived suppressor cells (MDSCs) in fresh peripheral blood and matched bone marrow samples from 42 MDS patients and the potential correlation with risk of disease progression to acute myeloid leukemia (AML). In peripheral blood, very low-/low risk patients had significantly lower median MDSC number (0.16×109/L(0.03–0.40)) compared to intermediate-/high-/very high risk patients, in whom median MDSC counts was 0.52×109/L(0.10–1.78), p < 0.005. When co-cultured with CD4+ effector T-cells (T-effectors), MDSCs suppress Teffector proliferation in both allogeneic and autologous settings. There was a positive correlation between the number of Tregs and MDSCs (Spearman R = 0.825, p < 0.005) in high risk and not low risk patients. We also investigated MDSCs' expression of bone marrow-homing chemokine receptors, and our data shows that MDSCs from MDS patients express both CXCR4 and CX3CR1 which might facilitate migration of MDSCs to bone marrow. Monocytic MDSCs(M-MDSCs) which are more frequent in the peripheral blood express higher levels of CX3CR1 and CXCR4 than the granulocytic subtype (G-MDSCs), and circulating M-MDSCs had significantly higher CX3CR1 expression compared to bone-marrow M-MDSCs in intermediate-/high-/very high risk MDS. Our results suggest that MDSCs contribute significantly to the dysregulation of immune surveillance in MDS, which is different between low and high risk disease. It further points at mechanisms of MDSCs recruitment and contribution to the bone marrow microenvironment.

1 November 2011 in Kidney International
Verified
Journal Article
Closed access
AKA. Marijn Kramer
A. Marijn Kramer
KSKarlijn J. van Stralen
Karlijn J. van Stralen
KJKitty J. Jager
Kitty J. Jager
FSFranz Schaefer
Franz Schaefer
EVEnrico Eugenio Verrina
Enrico Eugenio Verrina
JGJaap W. Groothoff
Jaap W. Groothoff

15 March 2024 in Leukemia
Verified
Journal Article
Closed access
PDF file
LSLiora M. Schultz
Liora M. Schultz
NJNikeshan Jeyakumar
Nikeshan Jeyakumar
AKAnne Marijn Kramer
Anne Marijn Kramer
BSBita Sahaf
Bita Sahaf
HSHrishi Srinagesh
Hrishi Srinagesh
LMLori Muffly
Lori Muffly

17 October 2024 in Blood
Verified
Journal Article
Open access
HSHrishikesh Srinagesh
Hrishikesh Srinagesh
CJClayton Jackson
Clayton Jackson
PSParveen Shiraz
Parveen Shiraz
NJNikeshan Jeyakumar
Nikeshan Jeyakumar
MHMark Hamilton
Mark Hamilton
LMLori Muffly
Lori Muffly
Although chimeric antigen receptor (CAR) T-cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies, many patients relapse and therefore strategies to improve antitumor immunity are needed. We previously designed a novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high response rates but relapse was common. Interleukin-15 (IL15) induces proliferation of diverse immune cells and can augment lymphocyte trafficking. Here, we report the results of a phase 1 clinical trial of the first combination of a novel recombinant polymer-conjugated IL15 receptor agonist (NKTR-255), with CAR19-22, in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Eleven patients were enrolled, 9 of whom successfully received CAR19-22 followed by NKTR-255. There were no dose-limiting toxicities, with transient fever and myelosuppression as the most common possibly related toxicities. We observed favorable efficacy with 8 of 9 patients (89%) achieving measurable residual disease–negative remission. At 12 months, progression-free survival for NKTR-255 was double that of historical controls (67% vs 38%). We performed correlative analyses to investigate the effects of IL15 receptor agonism. Cytokine profiling showed significant increases in IL15 and the chemokines CXCL9 and CXCL10. The increase in chemokines was associated with decreases in absolute lymphocyte counts and CD8+ CAR T cells in the blood and 10-fold increases in cerebrospinal fluid CAR-T cells, suggesting lymphocyte trafficking to tissue. Combining NKTR-255 with CAR19-22 was safe, feasible, and associated with high rates of durable responses. This trial was registered at www.clinicaltrials.gov as #NCT03233854.

23 December 2014 in OncoImmunology
Verified
Journal Article
Open access
JFJonathan Fisher
Jonathan Fisher
AKAnne-Marijn Kramer
Anne-Marijn Kramer
KGKenth Gustafsson
Kenth Gustafsson
JAJohn Anderson
John Anderson
Gamma delta T cells (γδT) are potent mediators of antitumor cytotoxicity and have shown promising efficacy in early phase clinical trials. Most is known about the tumoricidal properties of cells bearing the Vδ2 T cell receptor chain, but recent studies have demonstrated that cells with the Vδ1 chain and those with neither Vδ1 nor Vδ2 chains have properties which may make them more attractive anticancer effectors in adoptive immunotherapy.

18 December 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
HSHrishikesh K. Srinagesh
Hrishikesh K. Srinagesh
AKAnne Marijn Kramer
Anne Marijn Kramer
JBJohn H Baird
John H Baird
ARAgnes Reschke
Agnes Reschke
BSBita Sahaf
Bita Sahaf
MFMatthew J. Frank
Matthew J. Frank
Immune effector cell–associated hemophagocytic lymphohistiocytosis–like syndrome (IEC-HS) is a poorly characterized inflammatory toxicity of chimeric antigen receptor (CAR) T cells with high risk of mortality. In this study, we describe IEC-HS manifestations in patients with large B-cell lymphoma and B-cell acute lymphoblastic leukemia after CD22-directed CAR T cells. IEC-HS occurred in 19 of 54 patients (35%), including 11 grade 1 and 8 grade 2 or higher. IEC-HS was associated with higher nonrelapse mortality (NRM) yet lower relapse rates. CAR T-cell expansion in peripheral blood was significantly associated with IEC-HS severity. Cytokine profiling identified 41 cytokines primarily related to the IFNγ, TNFα, and IL1 families that significantly correlated with IEC-HS severity. We developed a parsimonious model composed of IFNγ, IL10, and IL1RA that correlated with grade 2+ IEC-HS on day 14, outperforming the full signature (AUC 0.93 vs. 0.75, P = 0.038). Thus, a cytokine signature with potential prognostic utility helps distinguish IEC-HS from inflammatory toxicities with overlapping symptoms. Significance: IEC-HS is a serious inflammatory toxicity of CAR T cells. We demonstrate that IEC-HS after CD22-directed CAR T-cell therapy is associated with lower rates of relapse yet higher NRM. CAR T-cell expansion and a 41-cytokine signature are associated with IEC-HS, and a simplified signature of IFNγ, IL10, and IL1RA precedes severe disease. See related commentary by Rocco and Shah, p. 163